M K Proteins Limited has informed the Exchange regarding Board meeting held on February 13, 2026 for approval of the Un-Audited Financial Results of the Company for the quarter and nine months ended 31st December, 2025.
MKPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
M K Proteins Limited reported its unaudited financial results for Q3 FY26 and nine months ended December 31, 2025, approved at a board meeting on February 13, 2026. Revenue from operations for Q3 FY26 stood at Rs. 89.56 crore, surging ~127% year-on-year from Rs. 39.48 crore in Q3 FY25. Nine-month revenue climbed ~81.5% to Rs. 236.93 crore versus Rs. 130.50 crore in the same period last year. However, profit after tax grew only marginally — Rs. 1.43 crore in Q3 FY26 (up ~4% YoY) and Rs. 5.69 crore for the nine months (up just ~1.6% YoY). The company operates in a single segment, manufacturing vegetable refined oil. Statutory auditor Subhash Sajal and Associates issued a clean limited review report with no qualifications or emphasis of matter.
Strong topline growth is a clear positive, but the sharp mismatch between revenue and profit growth suggests significant margin pressure, which may temper investor enthusiasm. Shareholders should watch whether the revenue ramp is sustainable and if margins recover in coming quarters before drawing a bullish conclusion on the stock.